Juvenile Diabetes Research Foundation (JDRF): Multiple opportunities - LOI

Glucose Responsive Insulin Discovery and Validation RFA - the discovery and validation of novel glucose responsive insulin (GRI) drugs for better treatment of insulin-dependent diabetes mellitus (IDDM) and reducing the burden of daily
management of the disease, particularly T1D. Funding: up to $500K / yr for up to 3 yrs.
Clinical Trials to Preserve Beta Cell Function and Delay Onset of Symptomatic Disease in the At-risk Setting for T1D - Expressions of interest are sought from investigators with access to patient cohorts of individuals with ≥2 T1D autoantibodies to conduct proof-of-concept clinical trials using intermediate trial outcomes/endpoints to inform larger and longer prevention trials. Repurposed and/or novel therapeutics (immune, inflammation, beta cell survival, metabolic, etc.) will be considered. Combination therapies, used either sequentially or simultaneously, for robust prevention will also be considered. Proposals with a focus on primary prevention will not be considered. Funding: $1.5 million/yr for up to 3 yrs.
http://jdrf.org/grant-center/grant-opportunities-and-deadlines/